Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
4.260
-0.140 (-3.18%)
At close: Apr 28, 2026, 4:00 PM EDT
4.170
-0.090 (-2.11%)
After-hours: Apr 28, 2026, 4:27 PM EDT
Coya Therapeutics Employees
Coya Therapeutics had 8 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$993,219
Profits / Employee
-$2,653,263
Market Cap
99.93M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8 | 0 | - |
| Dec 31, 2024 | 8 | 0 | - |
| Dec 31, 2023 | 8 | 2 | 33.33% |
| Dec 31, 2022 | 6 | 0 | - |
| Dec 31, 2021 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Inovio Pharmaceuticals | 112 |
| Fractyl Health | 100 |
| PepGen | 56 |
| Pyxis Oncology | 56 |
| Oncolytics Biotech | 29 |
| ProMIS Neurosciences | 11 |
| Aldeyra Therapeutics | 8 |
| KALA BIO | 6 |
COYA News
- 19 days ago - Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS - Business Wire
- 26 days ago - Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director - Business Wire
- 5 weeks ago - Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy - Business Wire
- 6 weeks ago - Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results - Business Wire
- 2 months ago - Coya Therapeutics Transcript: Status update - Transcripts
- 2 months ago - Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial - Business Wire
- 3 months ago - Coya Therapeutics Announces $11.1 Million Private Placement - Business Wire
- 3 months ago - Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders - Business Wire